Nail Your Sales Interview with the 30/60/90 Day Sales Plan
If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.

Now you can nail your interview with the 30 60 90 Day Sales Plan template with Audio Coaching. This simple tool will help you knock the socks off your interviewer and bury your competition.

To get the details: Click Here

[Close Window]
Medical Sales Jobs Websites - the best Medical Sales Jobs | Laboratory Sales Jobs | Medical Device Sales Jobs

Posts on ‘October 12th, 2009’

Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia

ROCKVILLE, Md., Oct. 12 (HSMN NewsFeed) — Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) announced today that it has entered into an agreement with Novartis Pharma AG to commercialize and develop Fanapt(TM) (iloperidone), Vanda’s anti-psychotic, in the U.S….
Biopharmaceuticals, Licensing
Vanda Pharmaceuticals, Novartis Pharma AG, Fanapt, iloperidone

Vascular Solutions and Zerusa Limited Announce FDA Market Clearance for the Next Generation Guardian II Hemostasis Valve

MINNEAPOLIS and GALWAY, Ireland, Oct. 12, 2009 –(HSMN NewsFeed) — Vascular Solutions, Inc. (Nasdaq:VASC ) and Zerusa Limited today announced that they have received 510(k) clearance with the FDA for the sale of the Guardian(r) II Next Generation hemostas…
Devices, FDA
Vascular Solutions, Zerusa Limited, Guardian II, hemostasis valve

Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia

Fanapt (iloperidone), an antipsychotic therapy, is indicated in US for the acute treatment of schizophrenia in adults, set for US launch in early 2010 Addition of Fanapt will strengthen Novartis psychiatry portfolio and build on history in schizophrenia…
Biopharmaceuticals, Licensing
Novartis, Novartis Pharma AG, Vanda Pharmaceuticals, Fanapt, iloperidone

RSB Spine, LLC, Announces FDA Clearance for the InterPlate(R) C-Ti as an Anterior Cervical Plate

CLEVELAND, Oct. 12 (HSMN NewsFeed) — RSB Spine, LLC, today announced that the InterPlate(R) C-Ti has been cleared for a new indication. When reclassification of interbody fusion devices occurred in 2007, the C-Ti was the first system cleared by the U.S….
Devices, Orthopaedic, Neurosurgery, FDA
RSB Spine, InterPlate, interbody fusion, anterior cervical plate